Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Secretary/CEO of subsidiary | May 10, 2021 | May 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TherapeuticsMD, Inc.
Report date May 10, 2021 · Filed May 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,752,703 |
Ending reported balance
After 2021-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-05-10 · Exercise / conversion · Acquired 103,500 · Balance 1,796,955 F1: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. Row 2 · 2021-05-11 · Sale · Disposed 44,252 · Balance 1,752,703 F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 207,000 |
Reported balance
After 2021-05-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-10 · Exercise / conversion · Disposed 103,500 · Balance 207,000 F1: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F5: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,582,373 |
Reported balance
Holding disclosure · report date 2021-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,582,373 F3: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021.
F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended.
F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
F5: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2021 Filed May 13, 2021 00:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 44,252 | $1.04 | $46,022.08 |
DisclosureSEC source: 0001387131-21-005567 · ownership.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Secretary/CEO of subsidiary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,752,703 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 103,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-005567 · ownership.xml · derivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Secretary/CEO of subsidiary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 Underlying: Common Stock · 103,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. F4 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F5 · derivative.exercise_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F5 · derivative.expiration_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F4 · balance_after: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 103,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-005567 · ownership.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Secretary/CEO of subsidiary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,796,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | OtherWarrant (right to buy) · Derivative | 179,000 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001387131-21-003348 · milligan-form4_030421.xml · derivative · entry 5 Milligan John C.K. IV · CIK 0001532230 · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 179,000 shares Expires 2021-03-06 F4 · derivative.exercise_date: The warrant vested quarterly in eight equal installments commencing June 30, 2011, becoming fully-vested on March 31, 2013. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Tax withholdingCommon Stock | 29,964 | $1.46 | $43,747.44 |
DisclosureSEC source: 0001387131-21-003348 · milligan-form4_030421.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,693,455 F1 · kind: On March 4, 2021, the reporting person exercised a warrant to purchase 179,000 shares of issuer common stock for $0.2444 per share. The reporting person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 29,964 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 149,036 shares. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | OtherCommon Stock | 179,000 | $0.24 | $43,747.60 |
DisclosureSEC source: 0001387131-21-003348 · milligan-form4_030421.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,723,419 Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 22:05 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 360,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-010306 · ownership.xml · derivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in two equal installments on November 24, 2021 and November 24, 2022. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in two equal installments on November 24, 2021 and November 24, 2022. Read SEC document |
| June 05, 2020 Filed Mar 9, 2021 02:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 434,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-003348 · milligan-form4_030421.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · President/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F2 · ownership.nature: Shares were owned by the Milligan Irrevocable Nonexempt Trust - 2014. These securities were held in a trust for the benefit of the reporting person's spouse and children. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2020 Filed Apr 2, 2020 00:33 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 310,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-003593 · milligan-form4_033020.xml · derivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,500 Underlying: Common Stock · 310,500 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. Read SEC document |
| March 30, 2020 Filed Apr 2, 2020 00:33 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantPerformance Stock Units · Derivative | 310,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-003593 · milligan-form4_033020.xml · derivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,500 Underlying: Common Stock · 310,500 shares Expires not disclosed F1 · shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · balance_after: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 21:03 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 72,000 | $2.75 | $198,000.00 |
DisclosureSEC source: 0001387131-19-007990 · milligan-form4_102519.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,544,419 F1 · shares: Represents a purchase from the underwriters in the issuer's public offering. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 21:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 72,000 | $2.75 | $198,000.00 |
DisclosureSEC source: 0001387131-19-007992 · milligan-form4_102519.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,544,419 F1 · shares: Represents a purchase from the underwriters in the issuer's public offering. Read SEC document |
| August 28, 2019 Filed Aug 31, 2019 01:49 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001387131-19-006605 · ownership.xml · derivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-08-28 F1 · derivative.exercise_date: Underlying shares vest as follows: 133,334 shares on the first anniversary date of the grant, 133,333 shares on the second anniversary date of the grant, and 133,333 shares on the third anniversary date of the grant. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 20:56 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 10,000 | $2.93 | $29,300.00 |
DisclosureSEC source: 0001387131-19-006246 · ownership.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,582,373 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.87 to $2.99, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4. F2 · ownership.nature: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:32 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 15,000 | $3.16 | $47,400.00 |
DisclosureSEC source: 0001387131-19-006150 · ownership.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,572,373 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to 3.19, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4. F2 · ownership.nature: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 129,127 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-006855 · milligan-form4_121718.xml · derivative · entry 8 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 129,127 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 129,127 | $3.64 | $469,634.90 |
DisclosureSEC source: 0001387131-18-006855 · milligan-form4_121718.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.53 to $3.735, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 129,127 | $0.10 | $13,145.13 |
DisclosureSEC source: 0001387131-18-006855 · milligan-form4_121718.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2018 Filed Dec 20, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 129,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-006855 · milligan-form4_121718.xml · derivative · entry 7 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,127 Underlying: Common Stock · 129,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2018 Filed Dec 20, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 129,000 | $3.75 | $483,750.00 |
DisclosureSEC source: 0001387131-18-006855 · milligan-form4_121718.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.87, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2018 Filed Dec 20, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 129,000 | $0.10 | $13,132.20 |
DisclosureSEC source: 0001387131-18-006855 · milligan-form4_121718.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 129,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-006632 · milligan-form4_120418.xml · derivative · entry 8 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,127 Underlying: Common Stock · 129,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 129,000 | $4.57 | $589,530.00 |
DisclosureSEC source: 0001387131-18-006632 · milligan-form4_120418.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.44 to $4.7, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 129,000 | $0.10 | $13,132.20 |
DisclosureSEC source: 0001387131-18-006632 · milligan-form4_120418.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 129,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-006632 · milligan-form4_120418.xml · derivative · entry 7 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,127 Underlying: Common Stock · 129,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 129,000 | $4.98 | $642,162.00 |
DisclosureSEC source: 0001387131-18-006632 · milligan-form4_120418.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.83 to $5.18, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 129,000 | $0.10 | $13,132.20 |
DisclosureSEC source: 0001387131-18-006632 · milligan-form4_120418.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2018 Filed Dec 1, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 129,128 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-006478 · milligan-form4_112818.xml · derivative · entry 8 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,127 Underlying: Common Stock · 129,128 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2018 Filed Dec 1, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 129,128 | $5.03 | $650,030.35 |
DisclosureSEC source: 0001387131-18-006478 · milligan-form4_112818.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.095, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2018 Filed Dec 1, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 129,128 | $0.10 | $13,145.23 |
DisclosureSEC source: 0001387131-18-006478 · milligan-form4_112818.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2018 Filed Dec 1, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 129,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-006478 · milligan-form4_112818.xml · derivative · entry 7 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,255 Underlying: Common Stock · 129,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2018 Filed Dec 1, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 129,000 | $4.89 | $630,294.00 |
DisclosureSEC source: 0001387131-18-006478 · milligan-form4_112818.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.765 to $5.065, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 28, 2018 Filed Dec 1, 2018 01:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 129,000 | $0.10 | $13,132.20 |
DisclosureSEC source: 0001387131-18-006478 · milligan-form4_112818.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 129,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-006314 · milligan-form4_111418.xml · derivative · entry 8 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774,255 Underlying: Common Stock · 129,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 129,000 | $4.99 | $643,581.00 |
DisclosureSEC source: 0001387131-18-006314 · milligan-form4_111418.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.78 to $5.11, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 129,000 | $0.10 | $13,132.20 |
DisclosureSEC source: 0001387131-18-006314 · milligan-form4_111418.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 129,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-006314 · milligan-form4_111418.xml · derivative · entry 7 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903,255 Underlying: Common Stock · 129,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 129,000 | $4.82 | $621,651.00 |
DisclosureSEC source: 0001387131-18-006314 · milligan-form4_111418.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.65 to $5.015, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 129,000 | $0.10 | $13,132.20 |
DisclosureSEC source: 0001387131-18-006314 · milligan-form4_111418.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 01:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005637 · milligan-form4_102318.xml · derivative · entry 8 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032,255 Underlying: Common Stock · 125,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 01:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 125,000 | $5.37 | $671,250.00 |
DisclosureSEC source: 0001387131-18-005637 · milligan-form4_102318.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.18 to $5.535, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 01:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 125,000 | $0.10 | $12,725.00 |
DisclosureSEC source: 0001387131-18-005637 · milligan-form4_102318.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2018 Filed Oct 26, 2018 01:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005637 · milligan-form4_102318.xml · derivative · entry 7 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,157,255 Underlying: Common Stock · 125,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2018 Filed Oct 26, 2018 01:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 125,000 | $5.33 | $666,250.00 |
DisclosureSEC source: 0001387131-18-005637 · milligan-form4_102318.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.15 to $5.435, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 23, 2018 Filed Oct 26, 2018 01:06 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 125,000 | $0.10 | $12,725.00 |
DisclosureSEC source: 0001387131-18-005637 · milligan-form4_102318.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005414 · milligan-form4_100918.xml · derivative · entry 8 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,255 Underlying: Common Stock · 125,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 125,000 | $5.76 | $719,625.00 |
DisclosureSEC source: 0001387131-18-005414 · milligan-form4_100918.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.4 to $6, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 125,000 | $0.10 | $12,725.00 |
DisclosureSEC source: 0001387131-18-005414 · milligan-form4_100918.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005414 · milligan-form4_100918.xml · derivative · entry 7 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,255 Underlying: Common Stock · 125,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 125,000 | $5.95 | $743,125.00 |
DisclosureSEC source: 0001387131-18-005414 · milligan-form4_100918.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.81 to $5.995, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.